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Abstract  
Rationale: Familial recurrence studies provide strong evidence for a genetic component to the 
predisposition to sporadic, non-syndromic Tetralogy of Fallot (TOF), the most common cyanotic 
congenital heart disease (CHD) phenotype. Rare genetic variants have been identified as important 
contributors to the risk of CHD, but relatively small numbers of TOF cases have been studied to date.  
Objective: We used whole exome sequencing (WES) to assess the prevalence of unique, deleterious 
variants in the largest cohort of non-syndromic TOF patients reported to date. 
Methods and Results: 829 TOF patients underwent WES. The presence of unique, deleterious 
variants was determined; defined by their absence in the Genome Aggregation Database (gnomAD) 
and a scaled combined annotation-dependent depletion (CADD) score of ≥20. The clustering of 
variants in two genes, NOTCH1 and FLT4, surpassed thresholds for genome-wide significance 
(assigned as P<5x10-8) after correction for multiple comparisons. NOTCH1 was most frequently 
found to harbour unique, deleterious variants. 31 changes were observed in 37 probands (4.5%; 95% 
confidence interval [CI]:3.2-6.1%) and included seven loss-of-function variants 22 missense variants 
and two in-frame indels. Sanger-sequencing of the unaffected parents of seven cases identified five de 
novo variants. Three NOTCH1 variants (p.G200R, p.C607Y and p.N1875S) were subjected to 
functional evaluation and two showed a reduction in Jagged1-induced NOTCH signalling. FLT4 
variants were found in 2.4% (95% CI:1.6-3.8%) of TOF patients, with 21 patients harbouring 22 
unique, deleterious variants. The variants identified were distinct to those that cause the congenital 
lymphoedema syndrome Milroy Disease. In addition to NOTCH1, FLT4 and the well-established TOF 
gene, TBX1, we identified potential association with variants in several other candidates including 
RYR1, ZFPM1, CAMTA2, DLX6 and PCM1. 
Conclusions: The NOTCH1 locus is the most frequent site of genetic variants predisposing to non-
syndromic TOF, followed by FLT4. Together, variants in these genes are found in almost 7% of TOF 
patients. 
 
Keywords: Congenital heart disease; Tetralogy of Fallot; whole exome sequencing  
Subject Codes: Congenital Heart Disease; Genetic; Association Studies  
Abbreviations: ASD, atrial septal defect; CADD, combined annotation-dependent depletion; CHD, 
congenital heart disease; CI, confidence interval; CNV, copy number variant; ExAC, Exome 
Aggregation Consortium; gnomAD, Genome Aggregation Database; GWAS, genome wide 
association study; HD, heterodimerisation domain; Ig, immunoglobulin; JAG1, Jagged1; LOF, loss-
of-function; MAF, minor allele frequency; NICD, NOTCH intracellular domain; SNP, single 
nucleotide polymorphism; TOF, Tetralogy of Fallot; VEGFR3, vascular endothelial growth factor 
receptor 3; VSD, ventricular septal defect; WES, whole exome sequencing.  
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Introduction 
 Congenital heart disease (CHD) is the most common type of birth defect, affecting 8/1000 live 
births (1). CHD covers a large spectrum of heterogeneous cardiovascular phenotypes that range from 
single, localised defects to more complex structural abnormalities. Tetralogy of Fallot (TOF) is the 
most common complex, cyanotic CHD with a prevalence of 1/3000 births (1,2). TOF is considered a 
malformation of the cardiac outflow tract which comprises four specific structural characteristics 
postnatally; a ventricular septal defect (VSD), anterocephalad deviation of the outflow septum with 
resultant overriding of the aorta, variable obstruction of the right ventricular outflow tract (pulmonary 
stenosis) and consequent hypertrophy of the right ventricle (2,3). Surgical interventions during 
infancy mean that 85-90% of TOF patients now survive until at least 30 years of age (1,4). However, 
this is not without consequence; event-free survival is just 25% after 40 years of age (5), since 
resultant scar tissue from surgery and pulmonary regurgitation cause significant morbidity in 
adulthood (6,7). 
 The cause of TOF is elusive and no single candidate gene can be held accountable for the 
disease phenotype. However, the genetic status of syndromic TOF sufferers has provided valuable 
insights into causative genes in some patients. Approximately 20% of cases are associated with a 
recognised syndrome or chromosomal anomaly (2). Most significantly, approximately 15% of TOF 
patients have 22q11.2 deletion syndrome, wherein the major causal gene is TBX1 (8,9). 
Approximately 80% of TOF cases are non-syndromic and there is generally no identifiable cause, 
largely due to their non-Mendelian patterns of inheritance (10-13). Accordingly, a polygenic genetic 
architecture has been hypothesised and genome-wide approaches have been undertaken to provide 
insights into the complex genetic alterations responsible for TOF and other CHDs (11,13-18).  
 Whole exome sequencing (WES) has been used successfully to identify new CHD candidate 
genes (14,17,19,20). Many lines of evidence indicate a degree of phenotypic specificity of variants in 
particular genes. For example, the spectrum of phenotypes caused by 22q11.2 deletion or mutations in 
TBX1 typically involves the outflow tract and great vessels (9,21,22), while Down syndrome or 
mutations in NKX2-5 typically cause septal defects (23,24). To date, no WES study of CHD has 
included substantial numbers of any homogeneous phenotype, which should a priori have the highest 
power to identify causal variants.  
 Here, we present findings from WES of the largest cohort of non-syndromic TOF patients 
reported to date. We performed WES in 829 TOF probands and identified the rarest and most 
deleterious protein-coding variants genome-wide. We sought evidence of pathological relevance for a 
subset of variants in the most significantly over-represented genes, based on the variants’ de novo 
occurrence and functional consequences in cellular models.   
Methods Summary 
 829 TOF probands were subjected to WES and unique (absent in the Genome Aggregation 
Database [gnomAD]), deleterious (combined annotation-dependent depletion [CADD] score of ≥ 20) 
variants were identified. Any variants observed in 1252 reference exome samples, that were analysed 
using the same approach as our case data, were eliminated from further consideration. Clustering 
analysis within the cases was then used to identify genes in which significantly more variants were 
observed than expected given background levels of variation across all genes. De novo variants were 
identified by Sanger sequencing of proband and parent samples where possible. Immunoblotting and 
luciferase assays were used to assess the expression and signalling activity of selected variants in the 
most strongly supported candidate gene. Detailed methods can be found in the Supplementary 
Materials.  
Results 
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Exome-wide analysis of unique, deleterious variants identifies the highest risk loci for non-
syndromic TOF 
 We assessed the incidence of unique, deleterious variants for 829 non-syndromic TOF cases. 
Any variants observed in 1252 reference exomes were removed from consideration as potential TOF 
susceptibility variants. The statistical significance of these findings was assessed for each gene using 
clustering analysis, which corrected for gene size (supplementary table 1). Two genes, NOTCH1 and 
FLT4, surpassed the threshold for genome-wide significance (assessed as P<5 x 10-8) (figure 1) and 
the unique variants identified in these genes are likely to be contributors to the pathogenesis of TOF. 
Combined, variants in NOTCH1 and FLT4 account for 6.9% of our TOF cohort, with no overlap 
between probands with variants in these genes. Additionally, several other genes that harbour an 
excess of variant clustering are also of interest; including RYR1 and TBX1, which have previously 
been implicated in CHD (25,26). In particularly, TBX1 is a well-established TOF risk gene which is 
principally responsible for the cardiac manifestations of 22q11 deletion; additionally, deleterious 
single nucleotide variants and small functionally significant intragenic deletions in TBX1 have been 
demonstrated in TOF patients (9,21). A further two genes, ZFPM1/FOG1 and CAMTA2, have roles in 
heart development and growth, respectively (27). DLX6 is negatively regulated by HAND2, a crucial 
transcription factor for heart morphogenesis (28) and PCM1 is a regulator of ciliogenesis, a process 
strongly linked to CHD (29). In addition, we specifically looked at the number of unique, deleterious 
variants in key cardiac transcription factors including NKX2.5 (30), GATA4 (31), HAND2 (12) and 
GATA6 (32), since pathogenic variants have previously been identified in TOF cases, typically by 
targeted candidate gene sequencing. Variants in these genes account for just 1.2% of cases in our 
cohort. When considering the top nine genes (or a P value cut-off of <0.01), 129 TOF cases had a 
unique, deleterious variant in one or more genes, accounting for over 16% of our patient cohort (table 
1). Just eight samples had variants in more than one of the top nine genes, highlighting the minimal 
overlap between probands with variants in these genes. Overall, NOTCH1 and FLT4 were found to be 
by far the most significant contributors to TOF; we therefore explored the variants in these two genes 
in greater detail.  
Variants in NOTCH1 are most commonly present in non-syndromic TOF 
 The NOTCH1 locus was most frequently found to harbour a unique, deleterious variant among 
TOF patients (P<2.22 x 10-16), with 37 probands harbouring 31 NOTCH1 variants (supplementary 
table 2), accounting for 4.5% of our TOF patient cohort (95% CI: 3.2% - 6.1%). Seven of the variants 
identified were loss-of-function (LOF), including three premature stop codons (p.R448X, p.W1638X 
and p.Q1733X), three single base pair deletions resulting in frameshifts and eventual premature 
truncation (p.G115fsX6, p.N147fsX128 and p.C1322fsX121) and a single base pair deletion in a 
splice site consensus sequence (c.5385-1delC). Of the remaining 24 variants, two were in-frame 
indels and 22 were missense variants. NOTCH1 is highly intolerant to LOF and missense variation, 
having a pLI of 1 and a missense z score of 4.48 on the Exome Aggregation Consortium (ExAC). We 
mapped the distribution of the 31 variants to the various domains of NOTCH1 (figure 2) and found 
the variants to be located throughout the protein with no significant clusters. The three frameshift 
mutations were located in the EGF-like repeats in addition to one truncating mutant, p.R448X, 
whereas the remaining two truncating variants were located in the heterodimerisation domain. Of 
particular interest, one variant located in EGF-like repeat 5, p.G193A (figure 2, bold), was identified 
in five unrelated patients and p.P143L (figure 2, bold) located in EGF-like repeat 4 was identified in 
three unrelated patients. Together, these two variants account for almost 1% of our TOF patient 
cohort. Interestingly, a further six NOTCH1 variants that map to the EGF-like repeats alter 
evolutionary conserved cysteine residues that contribute to disulphide bonds essential for maintaining 
the EGF structure (33). Of the four intracellular domain mutants, a missense variant in the Ankyrin 
repeats region, p.R2004L is particularly notable (figure 2, bold). R2004 is a surface exposed residue 
in Ankyrin domain 4 which is located in an interface region with the CSL transcription factor 
complex (34) and also located at an interface that binds the positive Notch regulator, Deltex (35).  
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 Deleterious mutations in other NOTCH pathway genes have been identified in patients with 
TOF including HEY2 (36) and JAG1 (37,38). For this reason, we compiled a list of NOTCH pathway 
genes using the MGI Gene Ontology Project and assessed the clustering of variants in these genes. Of 
166 genes tested, only NOTCH1 was found to have an excess of unique, deleterious variants 
(supplementary table 3). Hence, variants in other NOTCH pathway genes are not a major cause of 
TOF in our cohort. 
Evidence of pathological consequences for NOTCH1 variants 
 We investigated the occurrence rate of de novo variants in probands with NOTCH1 variants. Of 
the 31 probands in our TOF patient cohort that harboured unique, deleterious variants in NOTCH1, 
samples from both parents were available for seven probands and analysed for variant inheritance. 
Following Sanger sequencing, five of the seven NOTCH1 variants tested were identified as de novo; 
two of these were truncating variants, whereas the remaining three de novo variants were missense 
(table 2). These findings are in keeping with the results of previous WES experiments in CHD, where 
rare transmitted variants with strong bioinformatic support for functional impact, which are of 
presumed incomplete penetrance, have been uniformly encountered (14,17,20). 
 The NOTCH1 gene encodes an evolutionarily conserved transmembrane receptor that mediates 
cell-cell communication to govern cell fate decisions during development (39). S1 cleavage is an 
important step in the maturation of the NOTCH1 receptor. During this process, the 300 kDa 
translation product of NOTCH1 undergoes cleavage in the Golgi by furin-like convertase to generate 
two polypeptides of 180 and 120 kDa (40). To determine whether NOTCH1 variants affect S1 
cleavage, we assessed the expression of three NOTCH1 variants in comparison to wild type (WT) 
NOTCH1 by immunoblotting. The variants assessed were p.G200R, p.C607Y and p.N1875S (see 
figure 2); p.G200R is located in a conserved residue located within a β-hairpin turn within EGF5, and 
p.C607Y, located in EGF16, removes a conserved disulphide bond that normally would be expected 
to stabilise the EGF-domain conformation. p.N1875S is located in a residue that lies in a linker region 
between the RAM and Ankyrin repeat regions of the Notch intracellular domain. As expected, we 
observed two bands at 300 kDa (P300) and 120 kDa (P120), representing full length and cleaved 
NOTCH1 protein (40); the remaining 180 kDa product was not detectable due to the positioning of 
our FLAG-tag at the C-terminus (figure 3a). For WT NOTCH1, p.G200R and p.N1875S variants, we 
observe similar levels of both P300 and P120 (figure 3a). However, the p.C607Y variant exhibited 
perturbed S1 cleavage. Indeed, quantification confirmed that 5%±0.37% of NOTCH1 p.C607Y 
underwent cleavage in comparison to 57%±3.96% of WT NOTCH1 (P=0.0002; figure 3b). Hence, the 
p.C607Y variant affects S1 cleavage of NOTCH1, whereas the receptor is processed normally in the 
p.G200R and p.N1875S NOTCH1 variants. 
 Heterodimeric NOTCH1 is membrane tethered and undergoes further cleavage by γ-secretase 
which releases the NOTCH intracellular domain (NICD). NICD subsequently translocates to the 
nucleus where it interacts with transcription factor RBPJ to activate NOTCH target genes (39). To 
determine whether p.G200R, p.C607Y and p.N1875S variants affect NOTCH1 canonical signalling 
function, we assessed NOTCH signalling through the RBPJ transcription factor-dependent pathway 
following stimulation with immobilised Jagged1 (JAG1) ligand. The variants were overexpressed in 
HeLa cells and NOTCH1 signalling was assessed by RBPJ luciferase activity. Two of the three 
variants demonstrated reduced NOTCH signalling via RBPJ (figure 3c). The p.C607Y variant, that 
exhibited perturbed cleavage, significantly reduced NOTCH signalling by 47%±0.12% (P=0.008) 
compared to WT NOTCH1. Similarly, de novo variant p.N1875S reduced NOTCH signalling by 
38%±0.13% (P=0.02). The p.G200R variant exhibited similar canonical NOTCH signalling to WT 
NOTCH1 (P=0.67) (figure 3c), yet mapping of this variant to the three-dimensional NOTCH1 protein 
suggests structural implications (supplementary figure 2). Furthermore, p.G200R has also been 
reported in an independent study to segregate with CHD, supporting its pathogenicity (41). No 
significant differences were observed between WT NOTCH1, p.G200R, p.C607Y and p.N1875S 
variants in the absence of JAG1 ligand. In each transfection experiment, mRNA expression of WT 
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NOTCH1 and the three NOTCH1 variants was equal (supplementary figure 3), thus the differences in 
NOTCH1 signalling observed were not due to reduced mRNA expression of the variants. Hence, two 
variants identified in patients that were subjected to functional testing were shown to affect canonical 
NOTCH1 signalling. 
FLT4 variants found in TOF are distinct from those that cause Milroy Disease 
 The second most frequent locus of variant clustering in our TOF cohort was FLT4 (P=4.44 x10-
16). FLT4 encodes a receptor tyrosine kinase known as vascular endothelial growth factor 3 
(VEGFR3). VEGFR3 is indispensable for lymphatic development and FLT4 mutations are a known 
cause of the hereditary lymphoedema, Milroy disease. Strikingly, all mutations reported for Milroy 
disease are missense variants or in-frame indels located in the VEGFR3 protein kinase domain (figure 
4). In our TOF cohort of 829 probands, we report 22 unique, deleterious FLT4 variants in 21 TOF 
probands, accounting for 2.4% of cases (supplementary table 4). 16 of the FLT4 variants were LOF, 
including six premature stop codons (p.Y361X, p.Y369X, p.E896X, p.Q920X, p.R1031X and 
p.Q1126X) six indels resulting in frameshifts and premature truncation (p.P363fsX25, p.Q423fsX3, 
p.L636fsX3, p.Y853fsX20, p.N905fsX20 and p.Y1337fsX19) and four splice variants (c.3002-1C>T, 
c.3002-2T>C, c.2300C>G and c.2849del21). One premature stop codon, p.Y361X, was reported 
previously in a TOF proband and affected mother (25). The remaining six variants were missense, all 
of which were located in the immunoglobulin (Ig) domains of VEGFR3. FLT4 is extremely intolerant 
to both LOF and missense variation, as demonstrated by a pLI of 1 and missense z score of 3.73 on 
ExAC, respectively. In our 1252 reference exomes, no novel, LOF FLT4 variants were identified. 
Parent DNA was available for four probands. Three of the variants (p.Q920X, p.Y853fsX20 and 
c.2300C>G) were inherited from unaffected parents indicating incomplete penetrance, and one 
missense variant, p.C51W, was de novo (supplementary table 5). Frameshift variant Y853fsX20 was 
identified in two siblings with TOF and was inherited from the mother who was unaffected. Crucially, 
no missense or in-frame variants were found in the kinase domain, a feature unique to Milroy disease 
(figure 4). Our findings are in line with a recent publication by Jin et al (2017) that reports LOF 
variants in FLT4 in 2.3% of 426 TOF probands. Hence, we confirm this finding in the largest TOF 
cohort reported to date, approximately twice the size of previous studies, endorsing the importance of 
FLT4 as a major contributor to the incidence of TOF. 
Discussion 
 Despite TOF being the most common, severe cyanotic CHD, variants that could account for the 
high degree of genetic susceptibility, inferred from familial recurrence risk studies (42), are as yet 
unidentified. This study represents the largest WES investigation of sporadic, non-syndromic TOF 
performed to date. Using variant clustering analysis and stringent filtering, we identify two genes that 
reach genome-wide significance: NOTCH1 and FLT4. As an additional safeguard against false 
positive results due to systematic methodological differences between our cohort and the studies 
which contributed to the gnomAD database, we studied a set of over 1000 reference exomes in 
patients free from CHD; analysed in the same fashion as the case exomes, stringently removing any 
variant that appeared even once in the reference exome set from consideration as a potential TOF 
susceptibility variant. 
 We identify NOTCH1 as the major TOF susceptibility gene; 4.5% of patients carry 
heterozygous variants in NOTCH1, which based on gnomAD allele frequency, bioinformatic in silico 
prediction, and functional characterisation, we judged to be likely susceptibility alleles. With the 
exception of the 22q11 deletion, no single gene locus has been found to account for more TOF cases 
than NOTCH1. Seven of the variants were LOF, including truncating, frame shift and splice variants, 
whereas the remaining 24 variants were missense or in-frame indels and anticipated to be pathogenic. 
Five out of seven variants tested were de novo, adding to the evidence for pathogenicity; the 
remaining variants were transmitted from unaffected parents indicating incomplete penetrance. 
Previous sequencing studies of CHD have identified an association of NOTCH1 variants in cardiac 
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malformations including bicuspid aortic valve, aortic valve stenosis, coarctation of the aorta and 
hypoplastic left heart syndrome and TOF (43-47). However, the extent of NOTCH1 variant 
contribution to TOF has not been recognised until now. There are no clear distinctions between the 
type and location of NOTCH1 variants identified in TOF compared to those reported in other isolated 
cardiovascular abnormalities. We therefore propose that genetic background and/or environmental 
influences may specify phenotypic expressivity.  
 A possible role for NOTCH1 in non-syndromic TOF has previously been suggested by copy 
number variant (CNV) analysis. A study of 34 infants with non-syndromic TOF revealed two patients 
with CNVs encompassing the NOTCH1 gene (48). Additionally, a microdeletion including the 
NOTCH1 locus in a patient with TOF was identified in a study of CNVs in 114 TOF patients (49). A 
recent study that focused primarily on families with left-sided CHD also identified family members 
with TOF harbouring pathogenic mutations in NOTCH1 (44). Further indirect evidence for NOTCH1 
contribution to TOF came from a study that analysed the gene expression patterns in TOF patient 
right ventricles and found many genes from the NOTCH and WNT signalling pathways were 
significantly reduced. Interestingly, down-regulation of NOTCH signalling components was also 
observed in TOF patients with a 22q11.2 deletion (50), highlighting a common transcriptional 
signature between both syndromic and non-syndromic TOF, initiated by different genetic events. 
More recently, exome sequencing of 426 TOF patients that focused solely on LOF heterozygous 
variants did not identify an enrichment of NOTCH1 mutations in TOF patients (25). However, the 
present study involves, by a substantial margin, the largest TOF cohort studied by WES to date, 
including both LOF and damaging missense variants, hence providing the most accurate 
quantification thus far of the contribution of NOTCH1 variants to TOF risk. 
 Autosomal dominant germ-line mutations in the NOTCH1 gene are also one of the causes of 
Adams-Oliver syndrome (AOS) which is chiefly characterised by aplasia cutis congenita and 
terminal transverse limb defects. In addition to these features, around half of patients have congenital 
cardiac anomalies, including atrial septal defect (ASD), VSD, aortic valve stenosis, pulmonary valve 
stenosis and TOF (51,52). AOS is an extremely rare syndrome, with a prevalence of approximately 1 
in 225,000 (52). No patient in our cohort had diagnostic features of AOS. As with other CHDs 
associated with NOTCH1 variants, there are no clear distinctions between the NOTCH1 variants we 
have identified in TOF versus those that cause AOS, though no previously described AOS variant was 
present in our cases (51,52). Interestingly, the extra-cardiac features of AOS have been suggested to 
occur due to early embryonic vascular abnormalities (53), raising the possibility that AOS, TOF and 
other cardiac anomalies that occur due to mutations in NOTCH1 may be a spectrum of disorders.  
Other examples of syndromic genes that can cause isolated CHD, including TOF, are PTPN11 
(Noonan syndrome), (13,54), TBX5 (Holt-Oram syndrome) (55) and JAG1 (Alagille syndrome) (38). 
Determining the role of genetic background, environmental context and the specific NOTCH1 
variants in determining the severity of the cardiac phenotype and the occurrence of extra-cardiac 
malformations requires further research.  
 The association of NOTCH1 with a range of cardiac defects is consistent with the reported roles 
of NOTCH1 during heart development. Active NOTCH1 is observed in the trabecular endocardium 
and both global and endothelial-specific knockout of Notch1 in mice results in abnormal ventricular 
trabeculae and abnormal cardiomyocyte patterning (56). Relevant to TOF, Notch1 plays a role in the 
organisation of the outflow tract, which requires the specification of cells from both the neural crest 
and secondary heart field (57). Furthermore, Notch1 is important for endocardial epithelial-to-
mesenchymal transition, a process that is essential for cardiac valve formation (46,58). It should 
however be noted that all NOTCH1 variants we report are heterozygous. There are numerous reports 
of global and tissue specific Notch1 heterozygous mutant mice that appear phenotypically normal, 
with no obvious cardiovascular pathologies (59,60), although mice lacking endothelial/endocardial 
Notch1 in various backgrounds do present with TOF-like characteristics including septal defects and 
abnormal heart valves (61,62). This suggests endothelial NOTCH1 may be partly responsible for the 
cardiac malformations associated with TOF, and again, emphasising the importance of genetic 
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background. In further support of this, Notch1+/- in a predominantly 129S6 background developed 
aortic root dilation whereas Notch1+/- in a mixed background did not (63). Altogether, these reports 
highlight the importance of genetic background in disease expressivity and are consistent with the 
incomplete penetrance observed.  
 
 De novo mutations are a significant cause of early-onset genetic disorders, including CHD. Of 
the NOTCH1 variants identified in this study where parents were available, five of seven variants 
were found to be de novo. Similarly, we also found de novo variation in FLT4. For both of our 
genome-wide significant TOF genes, variants were also found to be inherited from unaffected parents, 
confirming the role of incompletely penetrant variants observed for other CHD genes and phenotypes 
(17,20). The incomplete penetrance is in keeping with the complex genetic aetiology of non-
syndromic TOF, in which families segregating the condition in a Mendelian fashion are rarely 
encountered and genetic background, in addition to in utero environmental factors, can be inferred to 
play significant roles. 
 For a subset of NOTCH1 variants, we provide evidence of functional impact by assessing 
canonical NOTCH1 signalling. The p.C607Y missense variant perturbed NOTCH1 receptor S1 
cleavage by the calcium-dependent enzyme, furin-like convertase. The S1 cleavage site is located at 
amino acids 1651 - 1654, some distance away from the variant. A similar observation has been 
reported by McBride et al (2008) where NOTCH1 variant p.A683T, identified in two patients with 
left ventricular outflow tract malformations, also perturbed S1 cleavage by similar levels. In both 
cases, this led to a 50% reduction in RBPJ luciferase activity (64). The mechanism by which such 
variants alter S1 cleavage to such an extent and reduce signalling by just 50% is unclear and requires 
further research. Furthermore, de novo variant p.N1875S was shown to have significantly reduced 
JAG1-induced NOTCH signalling relative to WT NOTCH1, providing further support as to the 
pathogenicity of de novo variants. p.G200R exhibited signalling levels similar to WT. However, in 
support of this variants pathogenicity, Blue et al (2014) identified the same NOTCH1 variant in an 
independent study; p.G200R segregated with disease in two cousins with right-sided CHD, including 
persistent truncus arteriosus, VSD, pulmonary atresia, and major aorto-pulmonary collateral arteries. 
Furthermore, a case of TOF was also reported in the preceding generation, although sequencing 
analysis was not carried out on this relative.  
 FLT4 was first associated with isolated TOF in a CNV analysis that identified a de novo 
duplication including FLT4, and a deletion of unknown inheritance upstream of FLT4 (18). Recent 
WES studies have also identified FLT4 to be a significant contributor to the incidence of TOF. Jin et 
al (2017) found 2.3% of TOF patients to have LOF FLT4 mutations. Furthermore, Szot et al (2018) 
also identified a FLT4 variant in a family with TOF (65). Using our larger cohort, we confirm FLT4 
variants to be a significant contributor to the incidence of TOF, with 2.4% of our cohort exhibiting 
deleterious FLT4 variants. In addition to LOF variants, we also identify a small number of pathogenic 
missense variants, including one variant that is de novo. The encoded product of FLT4, VEGFR3, has 
a well-established role in lymphatic development and in the adult, VEGFR3 expression is almost 
entirely restricted to lymphatic vessels (66,67). During embryonic development, VEGFR3 is also 
expressed in vascular endothelial cells and is crucial for blood vessel development. Loss of VEGFR3 
in mice leads to lethality at E9.5 due to defects in blood vessel formation and cardiovascular failure 
(68-70). This is prior to the emergence of lymphatics, suggesting VEGFR3 plays a unique role in 
cardiovascular development, independent of lymphangiogenesis. Importantly, patients with VEGFR3 
variants causing Milroy disease are not reported to have congenital heart malformations. The 
distinction between the locations of the mutations in FLT4 that cause Milroy disease in comparison to 
TOF may shed light on the evidently differing roles of the receptor in lymphatic versus heart 
development.   
 In addition to NOTCH1 and FLT4, we also report an excess of clustering in several other genes 
of interest including RYR1, ZFPM1/FOG1, CAMTA2, DLX6, PCM1 and known TOF gene, TBX1. A 
summary of in vivo and in vitro functional data currently available for these genes can be found in 
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supplementary table 7. Biallelic heterozygous mutations in RYR1 have previously been linked to 
CHD, including TOF, in a small number of cases (25,26). In addition, a mouse homozygous for the 
missense mutation I4895T, displayed notable delays in cardiogenesis including abnormal orientation, 
improper formation of the outflow tract and an ASD (71), suggesting a role in early heart 
development. ZFPM1/FOG1 encodes a GATA cofactor previously implicated in heart development. 
Fog1 null and endothelial lineage knockout mice develop heart malformations including a double 
outlet right ventricle and abnormal valve formation (27). Morpholino knockdown of fog1 also results 
in defective cardiac looping in zebrafish (72). While in vivo models suggest a role for FOG1 in heart 
development, we report a suggestive association of human FOG1 mutations with CHD for the first 
time. CAMTA2 interacts with NKX2-5, one of the core transcription factors controlling heart 
development. Together, Camta2 and Nkx2-5 promote cardiac hypertrophy in mice (73). CAMTA2 
was also identified as the likely candidate gene from a de novo CNV deletion at 17p13.2 in a patient 
with congenital pulmonary atresia (74). DLX6 encodes a homeobox protein involved with known role 
in cranial-facial morphogenesis. Interestingly in mice, Dlx6 is negatively regulated by Hand2 (28), a 
transcription factor crucial for cardiac morphogenesis. The significance of the relationship between 
HAND2 and DLX6 in the developing heart is not clear, although the formation of the great vessels 
and coronary arteries is reported to be independent of Dlx6 in mice (75). PCM1 encodes Pericentriolar 
Material 1, which is essential for centrosomal proteins and microtubule organisation. PCM1 also 
positively regulates ciliogenesis (76), a process which has been strongly linked to the development of 
CHDs (29). Following validation in an independently ascertained cohort, investigations of the role 
these genes during heart development may be of interest. It should be mentioned that ZNF717 also 
appears amongst our top TOF-associated genes. ZNF717 is a relatively small gene (less than 4kb) yet 
of all genes, exhibits the highest frequency of non-synonymous mutations per base pair in our 
reference exomes. For this reason, we do not consider ZNF717 to be a TOF candidate gene.  
 In summary, our findings which, in addition to NOTCH1 and FLT4, identified a number of 
potential novel TOF gene candidates, concur with previous studies regarding the marked locus 
heterogeneity of the condition. Among the genes that have been implicated in TOF thus far, our large 
study indicates that NOTCH1 is the most commonly involved. The two most commonly involved 
genes (NOTCH1 and FLT4) are also both crucial to angiogenesis, suggesting further investigation of 
common pathways between heart development and angiogenesis may be fruitful. In our top gene 
candidates, some mutations were de novo, but others were present in apparently asymptomatic 
individuals, indicating incomplete penetrance. Such incomplete penetrance has been frequently 
observed, for example, in Mendelian aortopathies, emphasising the importance of genetic background 
in structural cardiac and vascular diseases. Detailed phenotypic studies of mutation carriers who do 
not have overt CHD using advanced imaging may be of interest to delineate quantitative phenotypes 
potentially relevant to CHD. 
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Tables 
Table 1: The top gene candidates, ordered by levels of significance, following the clustering analysis 
of unique, deleterious variants 
Gene Variants P value Samples Cumulative sample count 
NOTCH1 31 <2.22 x 10-16 37 37 
FLT4 22 4.44 x 10-16 21 57 
RYR1 21 1.43 x 10-06 22 78 
TBX1 8 6.50 x 10-05 8 86 
ZFPM1 11 0.000266817 12 98 
ZNF717 9 0.001125519 10 106 
DLX6 7 0.002583786 8 114 
PCM1 11 0.003208801 11 123 
CAMTA2 9 0.007243157 9 129 
 
Table 2: Sequencing of parent samples to determine NOTCH1 variant inheritance 
Amino acid 
change Ref Alt LOF Impact Inheritance status 
p.G200V C A NO Missense variant DE NOVO 
p.C292Y C T NO Missense variant FROM UNAFFECTED MOTHER 
p.R448X G A YES Stop gained DE NOVO 
p.Q1495K G T NO Missense variant FROM UNAFFECTED FATHER 
p.C1549Y C T NO Missense variant DE NOVO 
p.W1638X C T YES Stop gained DE NOVO 
p.N1875S T C NO Missense variant DE NOVO 
Ref, reference allele; Alt, alternate allele; LOF, loss of function.  
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Figures with Figure Legends 
Figure 1: The top genes, in order of significance, in which non-syndromic TOF patients carry unique, 
deleterious variants. Bars indicate the respective significance levels of variant clustering for each 
gene, represented as –log P values. Circles represent the number of variants. The -log10(p) column for 
NOTCH1 (P<2.22 x 10-16) goes towards infinity and is 
shown as arbitrarily high. 
Figure 2: Unique, deleterious NOTCH1 variants in TOF patients. Diagrammatic representation of the 
NOTCH1 protein with known protein domains indicated. The location of NOTCH1 variants identified 
in our TOF cohort is shown. p.P143L, p.G193A and p.R2004L discussed in the main text are 
indicated (bold). ANK, ankyrin repeats; EGF, epidermal growth factor; HD, heterodimerisation 
domain; LBR, ligand binding region; LNR, Lin/Notch repeats; PEST, PEST domain; RAM, RBPJ-
associated molecule domain; TAD, transactivation domain; TM, transmembrane domain. 
Figure 3: (a) Immunoblot for FLAG to determine the expression and S1 cleavage of NOTCH1 
variants p.G200R, p.C607Y and p.N1875S in comparison to WT NOTCH1 following overexpression 
in HeLa cells. The two bands at 300 kDa (P300) and 120 kDa (P120) represent the full length and the 
S1-cleaved NOTCH1 protein. β-actin was used as a loading control. (b) Quantification of the 
percentage of S1 cleaved versus uncleaved NOTCH1 protein for WT NOTCH1 and NOTCH variants 
p.G200R, p.C607Y and p.N1875S. Error bars: mean ±SEM from three biological replicates and 
statistical significance was determined using two-tailed paired t-tests. (c) The effect of rare, 
deleterious NOTCH1 variants on Jagged-induced NOTCH signalling levels. NOTCH signalling 
activity was measured using a luciferase-based reporter system (RBPJ). HeLa cells were cultured with 
or without immobilised JAG1 ligand and co-transfected with RBPJ reporter constructs and WT 
NOTCH1, p.G200R, p.C607Y or p.N1875S. Firefly luciferase readings were normalised to Renilla 
luciferase readings to control for transfection efficiency and cell number. RBPJ activity was expressed 
relative to WT NOTCH1 for comparison. Error bars: mean ±SEM from four biological replicates, 
each with three technical replicates. Statistical significance was assessed using two-tailed paired t-
tests and the Hochberg step-up procedure to control for family-wise error rate.  
Figure 4: Unique, deleterious FLT4 variants in TOF patients. Schematic representation of FLT4 
structure with immunoglobulin (Ig)  domains and protein kinase domain, indicated. Top: FLT4 
variants identified in our TOF cohort (black) and those previously reported (grey). Bottom: FLT4 
missense or in-frame mutations reported in Milroy disease, all located in the protein kinase domain. 
 




